Industry top-down
Drug Manufacturers - Specialty & Generic
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
In the specialty and generic pharmaceutical industry, company performance varied significantly in Q1 FY2026. While some firms achieved strong double-digit revenue growth, others reported revenue declines. Earnings Per Share (EPS) also showed substantial fluctuations across companies, indicating a mixed trend. The industry's overall median revenue growth stood at approximately 5%.
- Significant disparity in sales growth rates by company (up to 110% increase, up to 12% decrease)
- Mixed performance in Earnings Per Share (EPS) growth/decline rates (up to 116% increase, up to 80% decrease)
- The industry median sales growth rate is approximately 5%
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| NBIXNEUROCRINE BIOSCIENCES INC | FY2026 Q1 | $572.6M | +11.1% | $0.08 | -81.0% | — |
| ELANElanco Animal Health Inc | FY2026 Q1 | $1.19B | -1.0% | $0.13 | +116.7% | — |
| ALKSAlkermes plc. | FY2026 Q1 | $306.51M | -12.5% | $0.13 | -38.1% | — |
| LNTHLantheus Holdings, Inc. | FY2026 Q1 | $372.76M | +0.8% | $1.02 | -45.5% | — |
| HIMSHims & Hers Health, Inc. | FY2026 Q1 | $586.01M | +110.7% | $0.20 | — | — |
| LQDALiquidia Corp | FY2026 Q1 | $3.12M | +5.0% | $-0.45 | — | — |
| INDVIndivior Pharmaceuticals, Inc. | FY2026 Q1 | $266M | -6.3% | $0.38 | — | — |
| AMRXAmneal Pharmaceuticals, Inc. | FY2026 Q1 | $695.42M | +5.5% | $0.04 | — | — |
| KNSAKiniksa Pharmaceuticals International, plc | FY2026 Q1 | $137.79M | +72.5% | $0.11 | — | — |
| BCRXBIOCRYST PHARMACEUTICALS INC | FY2016 Q2 | $32.67M | — | $-0.14 | — | — |
| PBHPrestige Consumer Healthcare Inc. | FY2026 Q3 | $841.24M | -0.8% | $3.28 | +2.8% | — |
| BHCBausch Health Companies Inc. | FY2026 Q1 | $2.26B | +4.9% | $-0.16 | — | — |
| HCMHUTCHMED (China) Ltd | FY2025 Q2 | $305.68M | -42.6% | $0.03 | -84.2% | — |
| HMDCFHUTCHMED (China) Ltd | FY2025 Q2 | $305.68M | -42.6% | $0.03 | -84.2% | — |
| ANIPANI PHARMACEUTICALS INC | FY2026 Q1 | $197.12M | +43.4% | $0.69 | -15.9% | — |
| GTBIFGreen Thumb Industries Inc. | FY2026 Q1 | $279.54M | +1.4% | $0.04 | -69.2% | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).